Literature DB >> 53086

Antigenic heterogeneity in patients with reactions in borderline leprosy.

R S Barnetson, G Bjune, J M Pearson, G Kronvall.   

Abstract

Fifteen patients with borderline leprosy who developed "reversal" reactions were studied from the inception of treatment. Thirteen showed an appreciable increase in lymphocyte transformation (LT) when preparations of Mycobacterium leprae were used as antigen. The LT responses to either "whole" or "sonicated" preparations of the bacillus in these 15 patients and in nine others also in reaction correlated with the clinical presentation. Those with skin disease predominating in the reaction showed an appreciable increase in LT when whole M leprae was used as antigen. Those with nerve disease predominating showed an increase with sonicated M leprae. In those with both skin and nerve disease there was an increase with both antigen preparations. The ratios of the LT test results (whole to sonicated M leprae) showed highly significant differences between the three groups.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 53086      PMCID: PMC1675388          DOI: 10.1136/bmj.4.5994.435

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  2 in total

1.  Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon.

Authors:  S N Wemambu; J L Turk; M F Waters; R J Rees
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

2.  The use of the voluntary muscle test in leprosy neuritis.

Authors:  C S Goodwin
Journal:  Lepr Rev       Date:  1968-10       Impact factor: 0.537

  2 in total
  10 in total

1.  Ultrastructural changes in blood vessels of peripheral nerves in leprosy neuropathy. II. Borderline, borderline-lepromatous and lepromatous leprosy patients.

Authors:  J Boddingius
Journal:  Acta Neuropathol       Date:  1977-09-26       Impact factor: 17.088

2.  In vitro lymphocyte stimulation in leprosy; simultaneous stimulation with Mycobacterium leprae antigens and phytohaemagglutinin.

Authors:  G Bjune
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

3.  Immunofluorescence studies in reactional leprosy with relevance to treatment.

Authors:  W R Faber; D L Leiker; R H Cormane
Journal:  Arch Dermatol Res       Date:  1978-05-31       Impact factor: 3.017

Review 4.  Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control.

Authors:  G Bjune; O Closs; R S Barnetson
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

5.  The suppressive effect of M. leprae on the in vitro proliferative responses of lymphocytes from patients with leprosy.

Authors:  I Nath; R Singh
Journal:  Clin Exp Immunol       Date:  1980-09       Impact factor: 4.330

6.  High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy.

Authors:  R Manandhar; N Shrestha; C R Butlin; P W Roche
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

7.  Plasma factors in delayed-type hypersensitivity. Augmentation of lymphocyte responses in borderline leprosy reactions.

Authors:  G Bjune; R S Barnetson
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

8.  C-reactive protein and apoB containing lipoproteins are associated with Mycobacterium leprae in lesions of human leprosy.

Authors:  M J Ridley; D S Ridley; F C De Beer; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

9.  Lymphocyte transformation test in leprosy: decreased lymphocyte reactivity to Mycobacterium leprae in lepromatous leprosy, with no evidence for a generalized impairment.

Authors:  W R Faber; D L Leiker; I M Nengerman; W P Zeijlemaker; P T Schellekens
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

10.  Antibody response in rabbits to immunization with Mycobacterium leprae.

Authors:  M Harboe; O Closs; B Bjorvatn; G Kronvall; N H Axelsen
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.